Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAC2
- Development stage
- Phase 1
- Lead developer
- Lineage Cell Therapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Injection (subcutaneous)
01
Overview
VAC2 is an allogeneic dendritic cell cancer vaccine developed as an off-the-shelf immunotherapy for cancer. It is produced from pluripotent stem cells using a directed differentiation method to generate nonproliferating mature dendritic cells, which are then loaded exogenously with a tumor antigen before administration. These dendritic cells act as potent antigen-presenting cells to stimulate the patient's immune system to recognize and attack cancerous cells expressing the target antigen but not normal adult tissues. The platform allows for modification to carry different antigens, including patient-specific tumor neo-antigens or viral antigens. VAC2 has been studied in Phase 1 clinical trials for advanced non-small cell lung cancer (NSCLC), where it demonstrated safety and some evidence of immune activation[1][2][4].
- Brand names
- VAC2VAC-2VAC 2
- Other names
- Dendritic cells - Lineage Cell Therapeutics
02
Targets
γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on VAC2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAC2.